TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04392297

Intervention type: DIAGNOSTIC_TEST
Intervention: Bood leukocyte subsets
Description: Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells

Intervention type: DIAGNOSTIC_TEST
Intervention: CMV specific T-cells
Description: CMV specific T-cells detected by flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: serum CMV IgM / IgG antibodies
Description: serum CMV IgM / IgG antibodies detected by ELISA
Study: NCT01953783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Description: Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity.
Study: NCT03438799

Intervention type: DEVICE
Intervention: Cordio System
Description: App, cloud and web device
Study: NCT02764489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate \[APCC\]), FEIBA NF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate \[APCC\]), FEIBA NF.
Study: NCT00415532

Intervention type: DRUG
Group type: OTHER
Intervention: Medical Standard of Care for ITP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study: NCT04657510

Intervention type: OTHER
Intervention: COVID-19
Description: Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)

Intervention type: OTHER
Intervention: COVID-19
Description: Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)
Study: NCT03128593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
Study: NCT00515073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m\^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m\^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic Radiation
Description: Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg IV given 30 minutes prior to chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: 300 mg IV given 30 minutes prior to chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg IV given 30 minutes prior to chemotherapy
Study: NCT00933660

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERC-training by instructor
Description: Standard way of training with an instructor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based training only
Description: Experimental way of training with a web based training application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based training with a personal training manikin
Description: Experimental way of training with a web based training application and a simple personal training manikin
Study: NCT05081674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alectinib
Description: 600mg 1OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200mg every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 6mg/kg every 4 weeks
Study: NCT02255799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily for 70 days.
Study: NCT05081674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150mg
Study: NCT02287337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: High velocity low amplitude thrust joint manipulation to cervical spine facet joints

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise
Description: Therapeutic exercises to the cervical, thoracic and scapular musculature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Therapeutic exercises to the cervical, thoracic and scapular musculature
Study: NCT02528578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermal stimulation delivered by a thermode.
Description: Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
Study: NCT02608359

Intervention type: DRUG
Intervention: Abiraterone Acetate
Description: This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
Study: NCT03804788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
Study: NCT04363411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: finger prick screening for BBV infections and questionnaires by outreaching methodology
Description: Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
Study: NCT03804788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygeine
Description: All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygeine
Description: All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
Study: NCT00630669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rubber band ligation
Description: placing rubber bands around the internal hemorrhoids

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar coagulation
Description: using electricity to cauterize
Study: NCT00593333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade Intramedullary Nail
Description: Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigen Trochanteric Femoral Nail
Description: Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
Study: NCT00660790

Intervention type: OTHER
Intervention: Intensified Treatment of risk factors
Description: Patients received a target oriented, intensified treatment of risk factors according to current national treatment guidelines
Study: NCT04072978

Intervention type: DEVICE
Intervention: Intraocular lens implantation
Description: Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.

Intervention type: DEVICE
Intervention: Intraocular lens implantation
Description: Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
Study: NCT03287466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: targeted oxygen therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: targeted oxygen therapy
Study: NCT01557491

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Straight Incision
Description: The incision will be made at a 90 degree angle to the surface of the scalp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bevelled Incision
Description: The Incision will be made at a 45 degree angle to the surface of the scalp.
Study: NCT03557710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Devaluing energy-dense foods for cancer-control
Description: A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Devaluing energy-dense foods for cancer-control
Description: A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Devaluing energy-dense foods for cancer-control
Description: A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
Study: NCT02780661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denture Cleanser Daily Use Period
Description: One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denture Cleanser Weekly Use Period
Description: One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
Study: NCT05521750

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
Study: NCT02933385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health screening
Description: Screen for diabetes, cholesterol, blood pressure and body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health screening
Description: Screen for diabetes, cholesterol, blood pressure and body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Closing events
Description: these aim to motivate the employees to continue into the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Closing events
Description: these aim to motivate the employees to continue into the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Closing events
Description: these aim to motivate the employees to continue into the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Health platform

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Health platform

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerometer provided
Description: Social Health Platform: employees can challenge themselves or each other.
Study: NCT04503148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled General Anesthetics
Description: Sevoflurane or desflurane for induction and maintenance of anesthesia
Study: NCT02884050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: antiepilepsy drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active placebo
Study: NCT04117360

Intervention type: OTHER
Intervention: Orthognathic surgery and Orthodontics
Description: This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
Study: NCT03618394

Intervention type: DIETARY_SUPPLEMENT
Intervention: MCT/ω-3-PUFA
Description: lipid emulsion

Intervention type: DIETARY_SUPPLEMENT
Intervention: Soybean Based
Description: lipid emulsion
Study: NCT05521750

Intervention type: PROCEDURE
Intervention: Transforaminal Percutaneous Endoscopic Lumbar Decompression
Description: TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
Study: NCT02482805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Exposure therapy for social anxiety disorder
Study: NCT02711696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GCED, Gluten Contamination Elimination Diet
Description: A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free  (Gluten Contamination Elimination Diet, GCED).
Study: NCT01449656

Intervention type: DEVICE
Intervention: LMA Proseal: control device
Description: LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization

Intervention type: DEVICE
Intervention: LMA Supreme: comparison device
Description: LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
Study: NCT00758953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol Once Weekly
Description: semi-solid
Study: NCT00758953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol Twice Weekly
Description: semi-solid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Once Weekly
Description: semi-solid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Twice Weekly
Description: semi-solid
Study: NCT02983734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: Partial agonist of N-methyl-D-aspartate (NMDA) receptor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sugar pill
Study: NCT02370966

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berry powder
Description: Berry and gingivitis trial

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Berry powder
Description: Berry and gingivitis trial
Study: NCT01773694

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Water Exposure
Description: The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.~On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing.
Study: NCT01567215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: silver nitrate
Description: Application 1 - 2 times a week for 3 - 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alcohol
Description: Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
Study: NCT02450942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDS
Description: 18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans